|Bid||0.00 x 30300|
|Ask||0.00 x 29100|
|Day's Range||3.35 - 3.35|
|52 Week Range||2.46 - 4.77|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Leading Nymox Pharmaceutical Corporation (NASDAQ:NYMX) as the CEO, Paul Averback took the company to a valuation of US$236.27M. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...
For Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. NYMX is exposedRead More...
Today I will take a look at Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) most recent earnings update (30 September 2017) and compare these latest figures against its performance over the past fewRead More...
On a per-share basis, the Nassau, Bahamas-based company said it had a loss of 6 cents. The biopharmaceutical company posted revenue of $78,400 in the period. Its adjusted revenue was $78,000. The company's ...